Citizens Rates Intellia Therapeutics (NTLA) buy, $30 Price Target

Citizens maintains a bullish outlook on Intellia Therapeutics with a $30 target, a 91.45% upside from the current price.

By EarningsIQ Research Desk · Published Jun 15, 2026, 11:01 AM EDT · Updated Jun 22, 2026, 6:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Citizens rated Intellia Therapeutics, Inc. ($NTLA) "buy" with a $30 price target on June 15, 2026.

Since the rating, $NTLA is up 5.6% after 1 week, down 12.6% after 1 month and down 23.5% to date (from the $14.92 close on Jun 15, 2026).

NTLA Intellia Therapeutics, Inc.

$11.42 +24.00% year to date

Daily close · Oct 16, 2026

Key Points

On June 15, 2026, Citizens reiterated its buy rating for Intellia Therapeutics, setting a $30 price target.
Citizens's $30 price target implies 91.45% upside from Intellia Therapeutics, Inc.'s ($NTLA) current $15.67 share price.
Intellia Therapeutics trades at $12.11, with a market cap of approximately $1.69 billion and a 52-week high of $28.25.
Insider purchases were reported on June 9, 2026, with several insiders acquiring shares without a disclosed price.

Get $NTLA trade alerts by text

We text you when insiders, Congress or big funds trade $NTLA. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Intellia Therapeutics, Inc. alert may contain errors. Disclosures

On June 15, 2026, Citizens reiterated its buy rating for Intellia Therapeutics, Inc. (NasdaqGM: NTLA), maintaining a price target of $30. This decision comes as the stock trades at around $12.11.

Other Institutional Activity in Intellia Therapeutics

ARK Investment Management LLC increased its holdings by 301,923 shares, ending with 14,509,247 shares valued at about $186 million. BlackRock, Inc. boosted its position by 1,878,957 shares, now holding 12,155,806 shares worth roughly $155.8 million. State Street Corp added 503,840 shares, bringing its total to 6,922,676 shares valued at approximately $88.7 million. D. E. Shaw & Co., Inc. also increased its stake by 397,113 shares, totaling 5,728,177 shares with a value of $73.4 million.

Intellia Therapeutics, Inc. Stock Up 29.1%

Shares of NasdaqGM:NTLA are trading near $12.11. Intellia Therapeutics has a market cap of about $1.69 billion. The stock has a 52-week low of $7.95 and a high of $28.25. It has a 50-day moving average of $13.63 and a 200-day moving average of $13.39. The company shows a forward P/E ratio that is not meaningful because it is not profitable, with a beta of 1.815.

12-month forecast

$NTLA price target

Intellia Therapeutics, Inc. daily closes and this analyst's $30 target. Not advice.

Recent Earnings

Intellia Therapeutics reported revenue of $66.1 million, reflecting a decline of 9.5%. The company has a net margin of 0% and a return on equity of -56.34%. The next earnings report is expected on August 6, 2026.

Insider Buying and Selling at Intellia Therapeutics, Inc.

On June 9, 2026, several insiders, including Fred Cohen, William Chase, and Brian Goff, each acquired 13,300 shares. Muna Bhanji and Georgia Keresty also purchased 9,200 and 13,300 shares, respectively. These transactions were not part of planned sales.

Analysts Set New Price Targets

On June 15, 2026, Citizens reiterated a buy rating with a $30 price target. Wedbush also reiterated its hold rating with a $12 target on the same day. Earlier, Bernstein maintained a hold rating with a $17 target on May 13, 2026. The consensus among 19 analysts is a buy recommendation, with an average price target of $26.63.

About Intellia Therapeutics

Intellia Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts. It focuses on developing therapies using CRISPR/Cas9 technology for genome editing. The company is working on treatments for conditions like transthyretin amyloidosis and hereditary angioedema. Intellia collaborates with various partners to advance its therapeutic pipeline.

Bottom Line

Citizens' reiterated buy rating underscores continued interest in Intellia Therapeutics' potential in genome editing technologies. With its current stock price and analyst targets, investors are closely watching its development efforts. As a reminder, analyst ratings are forward-looking and can change as new information becomes available.